Top Story
- Pricing & Reimbursement
Eli Lilly has agreed to a settlement to provide low-cost insulin to Minnesota patients, addressing a lawsuit accusing it and two other major insulin manufacturers of deceptive price inflation. Under the agreement, filed in a New Jersey federal court, Lilly will cap out-of-pocket expenses for its [...]
Latest Stories
- Data Analytics & Syndicated Reports
- Artificial Intelligence
Featured Webinars
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches
Thursday, February 29, 2024
Sponsor: Carelon Research
Integrated Evidence Generation Planning: Driving Successful Reimbursement and Life Cycle Management
Tuesday, February 27, 2024
Sponsor: OPEN Health
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
Gamida Cell Ltd. AVTE date announcement
Aerovate Therapeutics plans to announce top-line results for their Phase 2/3 trial of AV-101 - (IMPAHCT) on June 30, 2024. As of now, the drug has a 29.6% chance of moving on.
Aerovate Therapeutics rocketed [...]
Read MoreLongeveron AVIR date announcement
Now that the Phase 3 trial of Bemnifosbuvir (AT-527) - (SUNRISE-3) is completed, Atea Pharmaceuticals will announce their top-line results on March 31, 2024. The community is currently bullish on the prospects of progression, as [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest